Meet Our Plenary Speakers!
Who are the brilliant minds headlining PsychMed Israel 2024?
Our keynote speakers are pioneers in psychedelic medicine, eager to share their groundbreaking insights and journeys. Don’t miss your chance to connect with the best in the field!
Harriet de Wit
University of Chicago, USA
“Microdosing: What is the evidence?”
Harriet de Wit, PhD, is a Professor in the Department of Psychiatry and Behavioral Neuroscience at the University of Chicago. With over 40 years of experience, she studies the behavioral and neurobiological effects of psychoactive drugs.
Dr. de Wit has published over 300 papers, trained numerous students and fellows, and serves on several editorial boards. She has received multiple awards, including the Distinguished Achievement Award from the European Behavioural Pharmacology Society and the Lifetime Achievement Award from the Research Society on Alcoholism.
David Olson
University of California Davis, USA
‘Psychedelics and Related Plasticity-Promoting Neurotherapeutics’
Professor David E. Olson is a chemical neuroscientist specializing in CNS medicinal chemistry, neurobiology, and neuropharmacology.
He earned his Ph.D. in chemistry from Stanford University and completed postdoctoral training at the Broad Institute of MIT and Harvard. Since joining UC Davis in 2015, he has focused on the effects of small molecules on neural plasticity, learning, memory, and mood. In 2019, he co-founded Delix Therapeutics to develop non-hallucinogenic psychedelics for brain disorders. He is an associate editor at ACS Chemical Neuroscience and has received numerous awards, including the Jordi Folch-Pi Award and the Sigma Xi Young Investigator Award.
Jan Ramaekers
Maastricht University, The Netherlands
“Idiosyncracy of the Psychedelic Experience”
Dr Ramaekers works as a professor in psychopharmacology at Maastricht University in the Netherlands. His research combines methods from psychopharmacology, forensic toxicology and cognitive neuroscience to determine drug induced changes in human performance. In his work, he focuses on the impact of different substances of (ab)use, including cannabis, stimulants, opioids, novel psychoactive substances (NPS) and psychedelics on neuronal networks and human cognition. His work bears relevance in the context of drug development and therapeutics and in legal settings when evaluating the impact of drug exposure on human function.
Keren Tzarfaty
MAPS Israel & Hakomi Institute Israel
“Healing Oct 7- MDMA psychotherapy in a group”
Keren Tzarfaty, Ph.D, MFT is the cofounder of MAPS Israel (Multidisciplinary Association for Psychedelic Studies) and the co-founder of the Hakomi Institute of Israel, a Hakomi Trainer and a senior educator for MAPS. She is a clinical investigator in the MDMA PTSD FDA-approved clinical trial, examining the impact of MDMA-assisted psychotherapy on severe PTSD patients. She is also one of the founder of the new MA program at Haifa University: Integrative psychotherapy: Body, Mind, spirit.
Keren holds an MA in Somatic Psychology and a Ph.D. in East- West Psychology, both from the California Institute of Integral Studies in San Francisco. She specializes in integrating mindfulness-based psychodynamic psychotherapy with somatic psychotherapy, attachment psychotherapy, trauma psychology and transpersonal psychology. Her approach is grounded in traditional western psychologies as well as inspired by Eastern and Shamanic spiritual tradition
We are looking forward to seeing you there and revolutionise Psychadelic medecine together!
And the good news is:
It is not to late to register!